Nifty Pharma 22686.6 (0.50)
Nifty Bank 55458.85 (-0.48)
Nifty 50 25327.05 (-0.38)
SENSEX 82626.23 (-0.47)
Nifty IT 36578.25 (-0.47)
Nifty Smallcap 100 18504.55 (0.15)
Nifty Next 50 69736.6 (0.58)
Nifty Midcap 100 59094.35 (0.04)
NIKKEI 225 45045.81 (-0.57)
HANG SENG 26545.1 (0.00)
S&P 6734.5 (0.43)
13-Feb-2025
PAT of continuing business down 11% on lower sales
'Net sales (including other operating income) of WPIL for the quarter ended Dec 2024 has declined 11.40% to Rs 381.6 crore. Operating profit margin has declined from 16.24% to 12.61%, leading to 31.21% decline in operating profit to Rs 48.11 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 17.72% to 27.71%. Employee cost increased from 13.75% to 15.14%. Other expenses fell from 51.31% to 44.85%. Contract job process charges fell from 40.14% to 31.50%. Other income rose 23.33% to Rs 11.1 crore. PBIDT fell 24.99% to Rs 59.21 crore. Provision for interest rose 19.61% to Rs 11.16 crore. PBDT fell 30.97% to Rs 48.05 crore. Provision for depreciation rose 8.74% to Rs 8.34 crore. Profit before tax down 35.89% to Rs 39.71 crore. Share of profit/loss was 144.63% higher at Rs 5.92 crore. Provision for tax was expense of Rs 8.5...
(23-Aug-2025)
sales up 11%, net down 4%
(22-Aug-2025)
Sales down 1%, net down 91%
Sales up 24%, net up 20%
Sales up 25%, net up 40%
Results-Analysis (20-Aug-2025)
Net down 42% as OPM stay low
Analyst Meet / AGM-Conference Call (06-Aug-2025)
Optimistic about H2FY26
Results-Analysis (23-May-2025)
Net down 98% on weak operating show
Analyst Meet / AGM-Conference Call (23-May-2025)
Project business situation to see improvement from Q2FY26 onwards